EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome

NeurAxis Inc NRXS announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research.

The publication investigated changes in gastrointestinal symptoms and quality of life in 31 adolescent patients aged 11 – 18 years with functional abdominal pain disorders (FAPDs) before and after treatment with IB-Stim.

Also Read: EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids.

Following IB-Stim treatment, the study noted that:

• Patients reported significant reductions in abdominal pain, nausea, disability, and anxiety from baseline to week 4 (p < 0.05).
• Parent assessments reported significant improvement in the child’s quality of life based on physical function, psychosocial function, and generic core scale scores (p < 0.05).
• Parents also reported reduced abdominal pain, functional disability, and somatization in their children. 
• The global health scores also significantly improved based on patient and parent reports (p < 0.05).

IB-Stim therapy is its proprietary Percutaneous Electrical Nerve Field Stimulation technology.

IB-Stim is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 11-18 years.

Price Action: NRXS shares are down 21.1% at $4.10 premarket on the last check Tuesday.